|
|
 |
BioJENC aims to research and develop new and/or improved products for better health. Our current focuses are: 1) tumor vaccines, 2) viral vaccines, and 3) microbial
detection devices.
Brain tumor therapeutics: analogs, inhibitors, vaccines
BioJENC has a special interest
in tumors in general, brain tumors in particular. We are particularly interested in
astrocytomas including a relatively new entity named Rosetted Glioneuroma. We have
targeted several areas of interest: epidermal growth factor receptor, tumor protein 53, heparan sulfate proteoglycans, fibroblast
growth factors/receptors, and Fas/FasR.
Tumor vaccines: BioJENC has researched extensively to find links between virus and human cancer including brain tumors and has identified
a viral protein with sequence motifs similar to a tumor-associated protein. Given
that these two proteins also share a similar functionality, it is likely that these sequence motifs may play an essential
role contributing to their common functionality. BioJENC has designed peptides for
vaccine development targeting these sequence motifs.
Viral vaccines: BioJENC targets T-cell specific viral antigens for use as vaccine candidates against influenza (including seasonal flu viruses,
human-adapted swine A/H1N1 virus, and bird flu virus/H5N1), HIV, and malaria. Our
immediate goal in this area is to develop effective peptide vaccines against many strains of human pathogenic H5N1 virus including a
potential pandemic strain, many strains of A/H1N1 virus, and HIV. A peptide vaccine that
can induce an effective immune response to both A/H1N1 and H5N1 is under development.
Microbial detection devices:
BioJENC's sensitive
differential culture medium can be used to isolate and culture Gram negative and Gram positive bacteria including but not
limited to E. coli, Staphylococcus spp., Streptococcus spp., Pseudomonas spp., Enterobacter spp., Bacillus spp., and others. A rapid and sensitive reagent strip has also been developed to help differentiate nitrate-reducing
bacteria and acid-producing bacteria (results within seconds).
______________________________________________________________________________
|
|
|
|
|
BioJENC, LLC., Louisiana Emerging Technology
Center, Baton Rouge, LA 70803. USA. Tel: 225-615-8934, FAX: 225-615-8910.
|
|
|
|